{"entity":{"id":"capstone-1","kind":"trial","name":"CAPSTONE-1","aka":[],"tldr":"The trial that added Hengrui's PD-L1 antibody adebrelimab to chemotherapy for small cell lung cancer, with one of the larger survival gains seen in that disease.","summary":"462 patients, double blind. Median overall survival 15.3 versus 12.8 months (hazard ratio 0.72); two-year survival 31.3% versus 17.2%. NMPA approval March 2023. Together with ASTRUM-005 (serplulimab) it shows Chinese PD-(L)1 antibodies matching or exceeding the IMpower133 and CASPIAN benchmarks in a Chinese population.","status":"positive","asOf":"2026-09-10","links":[{"label":"ClinicalTrials.gov NCT03711305","url":"https://clinicaltrials.gov/study/NCT03711305"},{"label":"Lancet Oncol 2022","url":"https://doi.org/10.1016/S1470-2045(22)00224-8"}],"tags":["china"],"related":["astrum-005","impower133","caspian"],"cancers":["sclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["adebrelimab","carboplatin","etoposide"],"companies":["hengrui"],"institutions":["jilin-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":["cheng-ying"],"bottlenecks":[],"keyPapers":["paper-capstone-1-lancet-oncol-2022"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03711305","phase":"3","setting":"First-line extensive-stage small cell lung cancer, China: adebrelimab or placebo plus carboplatin and etoposide","sponsor":"Jiangsu Hengrui Pharmaceuticals","result":"OS 15.3 vs 12.8 months, HR 0.72.","started":"2018-12-30","startedType":"actual","yearReported":2022,"enrolled":462,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"Adebrelimab + EC","n":230,"value":15.3},{"name":"Placebo + EC","n":232,"value":12.8}],"hr":0.72,"source":"https://doi.org/10.1016/S1470-2045(22)00224-8"}]},"route":"/trials/capstone-1/","neighbours":{"trial":[{"id":"astrum-005","kind":"trial","name":"ASTRUM-005","route":"/trials/astrum-005/"},{"id":"caspian","kind":"trial","name":"CASPIAN","route":"/trials/caspian/"},{"id":"impower133","kind":"trial","name":"IMpower133","route":"/trials/impower133/"}],"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}],"institution":[{"id":"jilin-cancer-hospital","kind":"institution","name":"Jilin Cancer Hospital","route":"/institutions/jilin-cancer-hospital/"}],"person":[{"id":"cheng-ying","kind":"person","name":"Ying Cheng","route":"/people/cheng-ying/"}],"paper":[{"id":"paper-capstone-1-lancet-oncol-2022","kind":"paper","name":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-capstone-1-lancet-oncol-2022/"}]}}